HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...

Pfizer presents positive results from phase 3 BASIS study of Hympavzi in adults and adolescents with haemophilia A or B with inhibitors at ASH meeting: New York Tuesday, December ...

Months after a C-section, many women still feel a tugging or sharp pain deep in their abdomen, especially when standing up, ...

Using a murine model of venous thrombosis, scientists demonstrated that exposure to red light significantly reduces clot formation. Mice exposed to red light prior to inferior vena cava (IVC) ligation ...

In a surprising discovery, a "sticky molecule" that occurs naturally in our blood vessels could be both a culprit behind blood clots and organ failure during COVID and long COVID and the key to new ...

Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.